Dr Sacha Howell, Co-chief investigator of the trial from The Christie NHS Foundation Trust and The University of Manchester said: “We are thrilled with the FAKTION trial results and to have been top recruiters to the study here in Manchester.
"Every year around 6,100 people are diagnosed with breast cancer in the North West alone, that's 17 every day.
"The trial results and our own experience indicate that further evaluation of this potential treatment combination for patients with ER+ breast cancer is warranted.
"This bodes well for a larger phase 3 study which we hope would confirm the six month increase in overall survival seen in FAKTION. As breast cancer is the most common cause of cancer death worldwide the results of a follow-on phase 3 study could have a major impact globally.”